{"analyses":[{"ciLowerLimit":"0.581","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.065","groupDescription":"All analyses based on final DBL were descriptive only.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.786"},{"ciLowerLimit":"0.588","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.085","groupDescription":"All analyses based on final DBL were descriptive only.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.798"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.2","upperLimit":"8.3","value":"6.5"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"8.4","value":"6.4"},{"groupId":"OG002","lowerLimit":"5.9","upperLimit":"7.2","value":"6.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"106"}],"units":"Participants"}],"description":"PFS as assessed by IRC per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 1: Cemiplimab + Chemotherapy"},{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab","id":"OG001","title":"Part 1: Cemiplimab+AbbrevChemo+Ipilimumab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG002","title":"Part 1: Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Part 1 participants only","reportingStatus":"POSTED","timeFrame":"Up to a maximum of 82.2 months","title":"Part 1: Progression-free Survival (PFS) Per Independent Review Committee (IRC)","type":"SECONDARY","unitOfMeasure":"months"}